Japan Specialist

Mark Chadwick

Over 20 years experience in equities and asset management in Asia and Japan. Qualified CFA with experience analyzing companies as a buy-side analyst. In-depth knowledge of company fundamental analysis, corporate governance and valuations.

Equity Bottom-Up

<ul>
<li>Shiseido’s profit-first restructuring, including ¥25B cost cuts and SKU rationalization, lowers break-even levels, supporting operating margin recovery toward 7% by 2026 and 10% longer-term.</li>
<li>Strategic pivot toward prestige skincare strengthens pricing power and stability, positioning Shiseido to capitalize on Asia-Pacific demand while competitors face integration risks and category distractions.</li>
<li>Despite risks from China exposure, travel retail weakness, and intensified competition, successful execution could drive earnings recovery and valuation re-rating toward ¥4,000 fair value estimate.</li>
</ul>


Shiseido’s profit-first restructuring, including ¥25B cost cuts and SKU rationalization, lowers break-even levels, supporting operating margin recovery toward 7% by 2026 and 10% longer-term.
Strategic pivot toward prestige skincare strengthens pricing power and stability, positioning Shiseido to capitalize on Asia-Pacific demand while competitors face integration risks and category distractions.
Despite risks from China exposure, travel retail weakness, and intensified competition, successful execution could drive earnings recovery and valuation re-rating toward ¥4,000 fair value estimate.


Shiseido (4911) | Margin Recovery Driving Re-Rating Potential

Shiseido Company

Shiseido (4911) | Margin Recovery Driving Re-Rating Potential